News Sentiment

GLSI sentiment intelligence

Greenwich Lifesciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 19.80 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-10.0% over one week, -17.7% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Greenwich unifies 180-site FLAMINGO-01 trial protocol

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -10.0% Price reacting lower
Trend fit Trend inactive -17.7% over four weeks
Fair value 39.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 32
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
TradingKey 6
TradingView 5
Stock Titan 4
GlobeNewswire 4
Stock Traders Daily 3
Finviz 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 14
Regulatory and legal 8
Guidance 2
Analyst action 1
Balance sheet 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Investing.com Australia Direct company coverage

Greenwich LifeSciences expands trial enrollment in Europe By Investing.com

Greenwich LifeSciences (NASDAQ:GLSI) has announced that the European Medicines Agency approved the inclusion of both HLA-A02 and non-HLA-A02 patients in its FLAMINGO-01 Phase III clinical trial, aligning European and U.S. protocols. The company, which is evaluating GLSI-100 to pr

Tone
Positive 74/100
Event
Market update
Published
16 Jul 2026 12:10
Source
Investing.com Australia
www.marketscreener.com Direct company coverage

Greenwich LifeSciences Announces European Approval For Combining Both HLA Populations In FLAMINGO-01

Greenwich LifeSciences has received European Medicines Agency (EMA) approval to combine both HLA-A*02 and non-HLA-A*02 patient populations in its FLAMINGO-01 clinical trial, mirroring a prior FDA approval. This change standardizes the protocol across US and European sites, potent

Tone
Positive 71/100
Event
Regulatory and legal
Published
16 Jul 2026 12:10
Source
www.marketscreener.com
Stock Titan Direct company coverage

A breast cancer trial can now enroll patients who waited up to a year

Greenwich LifeSciences (Nasdaq: GLSI) announced that the European Medicines Agency (EMA) has approved combining both HLA-A*02 and non-HLA-A*02 patients in the randomized arms of its Phase III FLAMINGO-01 trial for GLSI-100, which aims to prevent breast cancer recurrences. This de

Tone
Positive 87/100
Event
Market update
Published
16 Jul 2026 11:10
Source
Stock Titan
Bitget Direct company coverage

Greenwich Lifesciences Inc announced that its commercial production of Gp2 has been approved for use in the Flamingo-01 study in Europe.

Greenwich Lifesciences Inc. has announced that its Gp2 commercial production has received approval for use in the Flamingo-01 study in Europe. This approval signifies a key regulatory achievement for the company as it advances its primary candidate products. The announcement was

Tone
Positive 70/100
Event
Regulatory and legal
Published
10 Jul 2026 05:12
Source
Bitget
GlobeNewswire Direct company coverage

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences (GLSI) announced European approval for the use of commercially manufactured GP2 in its FLAMINGO-01 Phase III clinical trial, following prior U.S. approval. All clinical sites across the U.S. and Europe will now use the same commercial lot of GP2 vials to tr

Tone
Positive 72/100
Event
Regulatory and legal
Published
10 Jul 2026 04:09
Source
GlobeNewswire
marketscreener.com Direct company coverage

Greenwich Lifesciences Receives European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich Lifesciences has received European Medicines Agency (EMA) approval to use its commercially manufactured GP2 lot in the FLAMINGO-01 clinical trial in Europe, following prior FDA approval for its use in the US. This means all US and European clinical sites, now numbering

Tone
Positive 70/100
Event
Regulatory and legal
Published
09 Jul 2026 18:03
Source
marketscreener.com
Investing.com South Africa Direct company coverage

Greenwich LifeSciences stock jumps as EMA approves commercial GP2 By Investing.com

Greenwich LifeSciences (NASDAQ:GLSI) shares increased by 7.7% after the European Medicines Agency (EMA) approved the commercial manufacture of GP2 for use in its FLAMINGO-01 clinical trial. This approval allows clinical sites in both the US and Europe to use the same GP2 lot, wit

Tone
Positive 73/100
Event
Regulatory and legal
Published
09 Jul 2026 16:03
Source
Investing.com South Africa
Moomoo Direct company coverage

Greenwich LifeSciences Says Commercially Manufactured GP2 Cleared for Trial in Europe

Greenwich LifeSciences announced that its commercially manufactured GP2 immunotherapy has been cleared for clinical trial in Europe. This marks a significant step towards global distribution and supports the company's planned Phase III trial in Europe for breast cancer patients.

Tone
Positive 81/100
Event
Market update
Published
09 Jul 2026 11:03
Source
Moomoo
grafa.com Direct company coverage

Greenwich LifeSciences Secures EMA Approval for Phase 3 GP2 Lot

Greenwich LifeSciences (NASDAQ:GLSI) has received European Medicines Agency (EMA) approval for its commercially manufactured GP2 immunotherapy lot for the Phase III FLAMINGO-01 clinical trial, standardizing the global supply chain after prior FDA approval. This approval allows fo

Tone
Positive 71/100
Event
Regulatory and legal
Published
09 Jul 2026 10:15
Source
grafa.com
Stock Titan Direct company coverage

Europe joins U.S. in using commercial GP2 for Greenwich’s breast cancer trial

Greenwich LifeSciences (GLSI) announced that the European Medicines Agency (EMA) has approved the use of its commercially manufactured GP2 lot in the Phase III FLAMINGO-01 breast cancer trial. This approval follows earlier clearance from the FDA for use in the U.S., meaning all 1

Tone
Positive 72/100
Event
Regulatory and legal
Published
09 Jul 2026 10:10
Source
Stock Titan
Stock Traders Daily Direct company coverage

The Technical Signals Behind (GLSI) That Institutions Follow

This article analyzes Greenwich Lifesciences Inc. (NASDAQ: GLSI), highlighting weak near and mid-term sentiment which could challenge its long-term positive outlook. It provides technical signals, institutional trading strategies (position, momentum, risk hedging), and multi-time

Tone
Negative 37/100
Event
Guidance
Published
07 Jul 2026 18:14
Source
Stock Traders Daily
Finviz Direct company coverage

GLSI - Greenwich LifeSciences Inc Latest SEC Filings

This article provides the latest SEC filings and comprehensive financial data for Greenwich LifeSciences Inc (GLSI). It includes key financial metrics, stock performance, insider ownership, institutional ownership, and analyst recommendations, offering a detailed snapshot of the

Tone
Negative 33/100
Event
Analyst action
Published
05 Jul 2026 02:40
Source
Finviz
Finviz Direct company coverage

GLSI - Greenwich LifeSciences Inc Revenue Breakdown

This article provides a detailed financial breakdown for Greenwich LifeSciences Inc (GLSI), including its stock performance, market capitalization, income, sales, and various financial ratios. It highlights key metrics such as insider ownership, institutional ownership, volatilit

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 04:09
Source
Finviz
Finviz Direct company coverage

GLSI - Greenwich LifeSciences Inc Options

This article provides a detailed financial overview of Greenwich LifeSciences Inc (GLSI), including its recent stock performance, key financial metrics, ownership data, and various valuation ratios. The company's stock closed at $22.00, experiencing a 7.17% decrease. It also high

Tone
Negative 41/100
Event
Market update
Published
04 Jul 2026 02:10
Source
Finviz
TradingView Direct company coverage

Greenwich LifeSciences, Inc. Financial Disclosures & SEC Filings

This article provides a compilation of Greenwich LifeSciences, Inc.'s financial disclosures and SEC filings, including quarterly and annual reports detailing net losses, R&D spending, and cash positions. It also mentions key corporate events such as conference presentations and u

Tone
Negative 35/100
Event
Balance sheet
Published
02 Jul 2026 18:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI

This article provides "Price to book forward" information for Greenwich LifeSciences, Inc. (NASDAQ:GLSI). It appears to be a financial data point presented on the TradingView platform, noting that the market is closed with no trades. The minimal content suggests this is primarily

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 03:39
Source
TradingView
Stock Traders Daily Direct company coverage

Precision Trading with Greenwich Lifesciences Inc. (GLSI) Risk Zones

This article from Stock Traders Daily provides a detailed analysis of Greenwich Lifesciences Inc. (GLSI), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It outlines several AI-generated trading strategies—Position, Momentum Breakout, and Risk

Tone
Negative 39/100
Event
Guidance
Published
27 Jun 2026 13:13
Source
Stock Traders Daily
TradingView Direct company coverage

Price to sales forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI

This article provides a brief snapshot of the "Price to sales forward" metric for Greenwich LifeSciences, Inc. (NASDAQ: GLSI). The content is minimal, essentially displaying the company's stock ticker and market information. It indicates that the market is closed with no current

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 22:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI

This article focuses on the enterprise value to EBIT forward for Greenwich LifeSciences, Inc. (NASDAQ: GLSI). The content appears to be a financial data page from TradingView, providing an overview of the company's financial metrics within the Biotechnology sector. It highlights

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 19:10
Source
TradingView
TradingKey Direct company coverage

Greenwich Lifesciences Inc (GLSI) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Greenwich Lifesciences Inc (GLSI), noting its strong financial status and low operating efficiency, with a current financial score of 6.92. It ranks 187 out of 388 in the Biotechnology & Medical Research industry. The report highlight

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 09:09
Source
TradingKey
TradingKey Direct company coverage

Greenwich Lifesciences Inc (GLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Greenwich Lifesciences Inc (GLSI) has an earnings forecast score of 8.00, placing it 165th in the Biotechnology & Medical Research industry. Analysts project an average price target of $42.00, with a consensus "Buy" rating based on two analysts. The company's EPS for the previous

Tone
Positive 66/100
Event
Earnings
Published
18 Jun 2026 07:14
Source
TradingKey
TradingKey Direct company coverage

Greenwich Lifesciences Inc (GLSI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Greenwich Lifesciences Inc (GLSI) focusing on its dividend history and stock splits. It notes that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also presents current stock da

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 19:41
Source
TradingKey
TradingKey Direct company coverage

Greenwich Lifesciences Inc (GLSI) Institutional Confidence

Greenwich Lifesciences Inc (GLSI) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 19.42% quarter-over-quarter to 11.38%. Patel (Snehal) is the lar

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 19:09
Source
TradingKey